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Instruments Evaluating the Clinical Findings of Laryngopharyngeal
Reflux: A Systematic Review
Jerome R. Lechien, MD, PhD, MSc; Antonio Schindler, MD, PhD; Lisa G. De Marrez, MD;
Abdul Latif Hamdan, MD, MPH, FACS; Petros D. Karkos, MD, PhD; Bernard Harmegnies, PhD;
Maria Rosaria Barillari, MD, PhD; Camille Finck, MD, PhD†; Sven Saussez, MD, PhD†
Objectives: To identify the instruments for evaluating the clinical findings (ICFs) of laryngopharyngeal reflux (LPR)
designed for use with regard to diagnosis and treatment effectiveness.
Methods: The PubMed, Scopus, and Cochrane databases were used to search for subject headings following Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Three investigators retrieved relevant
studies published between 1990 and 2018 describing the evolution of laryngopharyngeal findings throughout LPR treatment.
Issues of clinical relevance, that is, LPR diagnosis, treatments, and signs assessed for diagnosis or as therapeutic outcomes,
were assessed. The investigators also evaluated the psychometric properties (conceptual model, content validity, consistency,
reliability, concordance, convergent validity, known-groups validity, responsiveness to change, and interpretability) of the ICF.
The risk of bias was assessed with the tool of the Clarity Group and Evidence Partners.
Results: The search identified 1,227 publications with a total of 4,735 LPR patients; of these studies, 53 met the inclusion
criteria. Of these 53 studies, we identified 10 unvalidated and six validated ICFs. None of the validated ICFs included all the
psychometric properties. The main identified deficiencies related to ICF psychometric validation included variable construct
validity, disparate and uncertain reliabilities, and a lack of interpretability. The lack of consideration of certain LPR laryngeal
and extralaryngeal signs is the main weakness of ICFs, biasing content, and construct validities.
Conclusion: The low specificity of LPR signs, the lack of consideration of many findings, and the absence of a gold standard for
diagnosis constitute barriers to the further validation of these ICFs. Additional studies are needed to develop complete and reliable ICFs.
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INTRODUCTION
Laryngopharyngeal reflux disease (LPRD) is the
back flow of gastric or gastroduodenal contents into the
laryngopharynx where it comes in contact with tissues of
the upper aerodigestive tract.1 According to some U.S.
reports, LPRD affects approximately 10% of outpatients
of the ear, nose, and throat (ENT) department consulta-
tion and up to 50% of patients in the voice center.2,3 The
most common complaints related to LPRD include
hoarseness, sore throat, odynophagia, cough, throat clear-
ing, globus sensation, and excessive phlegm.4,5 Usual gas-
troesophageal reflux disease (GERD) findings such as
heartburn, regurgitations, and esophagitis do not neces-
sarily concern the majority of patients, leading some oto-
laryngologists to distinguish LPR and GERD as two
different clinical entities.4,6 Moreover, LPRD is character-
ized by a myriad of clinical signs such as laryngeal edema
and erythema, ventricular obliteration, laryngeal kerato-
sis, posterior commissure hypertrophy, pharyngeal wall
edema and erythema, tongue tonsil hypertrophy, and ery-
thema of the anterior pillar.5,7–10 The exact incidence of
these signs remains unknown given the mixed results in
the literature.
Today, there is no gold standard for the diagnosis of
LPRD because pH impedance monitoring has many
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weaknesses such as the cost of the procedure or high
false-positive and false-negative rates. Regarding the
weaknesses of pH impedance metry, many physicians
consider the evolution of signs and symptoms throughout
empirical treatment as cost-effective diagnosis methods
for LPRD.6,11 LPRD clinical findings must be assessed
with an adequate knowledge of the pathology and with
methodological rigor. In fact, the evaluation of both the
signs and symptoms related to LPRD using poor instru-
ments with defective methods can have substantial impli-
cations for treatment effectiveness, thereby leading to
inaccurate and equivocal conclusions. Recent studies have
summarized and analyzed patient-reported outcome mea-
surements;12 to date, however, no study has provided a
systematic review of the clinical instruments (assessing
signs) used with regard to LPRD.
The first objective of this systematic review was to
identify the instruments assessing the clinical findings
(ICFs) of LPRD used in both the diagnosis and treatment
effectiveness. The second objective was to assess the fre-
quency of ICFs. Finally, the third objective was to evalu-
ate the psychometric properties of these ICFs.
MATERIALS AND METHODS
The criteria for considering studies for this systematic
review were based on the Patient/Problem, Intervention, Com-
parison, Outcome (PICO) framework.
Types of Studies
Clinical and observational studies published as full-scale
original articles in peer-reviewed journals. The studies should be
written in English or French.
Participants
Adults with suspected or confirmed LPRD. Patients with
positive pH metry/impedance and patients who positively
responded to an empirical treatment were considered LPR
patients. Patients included in the study on the basis of symptoms
± signs without additional examination were considered sus-
pected LPR subjects.
Intervention
The patient may have been treated with medication
(i.e., proton-pump inhibitors [PPIs]), alginate, antihistamine,
gastroprokinetic), or diet and behavioral changes, or placebo for
at least 4 weeks.
Comparison and Outcomes
Authors may have followed natural history of symptoms
with no active treatment or not conducted any comparisons.
Search Strategy
The PubMED, Cochrane Library, and Scopus databases
were searched to identify studies published between January
1990 and April 2018 that used ENT signs with or without vali-
dated ICFs for both the diagnosis and follow up of LPRD. The
keywords applied were “reflux,” “laryngopharyngeal,” “laryngitis,”
“sign(s),” “measurement,” and “gastroesophageal.” These words
were combined in distinct ways to generate broad research results
(Fig. 1). References were also obtained from the citations of
retrieved publications or the systematic review. The methodology of
this review strictly adhered to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines.13
Data Selection, Extraction, and Analysis
Three authors (J.R.L., M.R.B., and L.G.DM.) independently
reviewed the abstracts of all the identified studies and selected
those that met the inclusion criteria for full texts. The authors of
the publications were contacted for additional information about
their studies when necessary. The investigators compared the
age, gender, author, and center data whenever they were avail-
able to avoid multiple inclusions of patients. When the same
patients were described in more than one publication, authors
used only the data reported in the larger and more recent publi-
cation. The authors did not exclude any publication based on
quality. The following types of studies were excluded: studies
focusing on only patient-reported outcomes or health-related
quality of life instruments.
Procedure of Outcomes Analysis
The investigators independently identified all studies in
which LPRD signs were used as therapeutic outcomes. From this
database, the investigators extracted potential ICFs that were
assessed with regard to name; acronym; year and reference of
the initial publication (development); language and country of
origin; objective (diagnosis, therapeutic tool, or both) and target
population; characteristics of the included patients for instru-
ment development; setting of development (tertiary care or com-
munity); and the ICF characteristics including rated signs, type
of scale (i.e., visual analog scale), number of items, calculation,
and potential subscales. The investigators analyzed the following
properties to assess the psychometric developmental properties
of each ICF: 1) conceptual model, 2) content validity, 3) internal
consistency, 4) test–retest reliability, 5) concordance, 6) conver-
gent validity, 7) known-groups validity, 8) responsiveness to
change, and 9) interpretability and scoring. The analysis of these
properties was conducted with regard to definitions described in
Table I. The properties’ definitions were based on previous ana-
lyses of clinical outcome measurement instruments.12,14,15 Dis-
crepancies in the analysis of psychometric properties were
resolved by discussion with senior otolaryngologists (C.F. and S.
S.). To ensure wide inclusion, we considered ICFs as validated
only when the authors validated at least one developmental mea-
surement property. Thus, at the end of the analysis, we docu-
mented validated and unvalidated ICFs. The validation of ICFs
in studies was also evaluated for the risk of epidemiological bias
using the Tool to Assess the Risk of Bias in Cohort Studies devel-
oped by the Clarity Group and Evidence Partners.16
RESULTS
Search Results
A total of 72 relevant studies were identified from the
PubMED, Scopus, and Cochrane databases. Of these refer-
ences, 53 met our inclusion criteria (specifically, studies
using ENT signs for LPRD diagnosis and as therapeutic
outcomes). A total of 4,735 suspected or confirmed LPR
patients were included within these articles.4,5,9–11,17–63 A
detailed description of included studies and characteristics
(i.e., the number of patients, assessed signs, and treatment)
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is displayed in Table II. Of the 53 papers, six validated
(i.e., Reflux Finding Score [RFS], Chronic Posterior Laryngi-
tis Index [CPLI], Laryngeal Reflux Grade [LRG], laryngo-
pharyngeal reflux disease index [LRDI] and Laryngeal
Grading Scale [LGS]; and Table III) and 10 unvalidated
ICFs were extracted. Unvalidated ICFs are available in an
additional table (Supporting Table SI). The flowchart of this
study is shown in Figure 1.
LPRD Findings and Instruments
All standardized or unstandardized instruments
were developed at secondary or tertiary academic centers
between 1997 and 2014. Specifically, most of the ICFs
were elaborated within otolaryngology or head and neck
surgery departments with or without collaboration with
gastroenterology departments for monocenter (N = 15) or
multicenter (N = 1) prospective studies. The instruments
were developed in the United States (N = 8), Austria
(N = 3), India (N = 1), Japan (N = 1), Lithuania (N = 1),
Spain (N = 1), and Australia (N = 1). All studies were
published in the English language. The targeted popula-
tions were patients with confirmed or suspected LPR,
with mean ages of 50.12 and 40.70 years in the validated
and unvalidated ICF groups, respectively. The sex ratio
of both groups was 6 females/4 males As Tables III and
Supporting Table SI). show, ICFs were mainly developed
as a therapeutic outcome (N = 13), occasionally for both
diagnosis and therapeutic outcomes (N = 3).
The majority of the ICFs used a visual analog scale
(VAS) to rate the severity or presence of LPRD signs with
numerous items ranging from 3 to 12 (Table III). When
the score was not used to assess the prevalence of signs,
the calculation method was primarily based on the sum of
each item score (N = 10). Three studies did not calculate a
total score and only reported individual item scores.
An important level of heterogeneity characterizes
the different ICFs with regard to the evaluated findings.
In fact, certain laryngeal signs were frequently evaluated
(i.e., laryngeal/arytenoids erythema, edema, posterior
commissure hypertrophy, vocal fold edema, erythema,
granuloma, and granulation) by comparison with pharyn-
geal and other signs. This heterogeneity was more preva-
lent in the current literature when focusing on all studies
that assessed LPRD signs throughout treatment
(Table IV). The most frequently assessed findings as ther-
apeutic outcomes were those described with regard
to RFS.
TABLE I.
Definition of the Measurement Properties of Signs of Instruments Analyzed in the Study.
Domain Definition
Conceptual model
Construct definition It provides a rationale for and description of the concepts and target population that a measure is intended to assess.
Target population
Expected subscales
Content validity It refers to evidence that an instrument is appropriate for its intended use. Items and conceptual domains must be relevant to the
targeted population.
Content expert involved The instrument’s development of signs must include direct input from experts. There should be a clear description of the process
by which included signs were derived.
Description of item
development
The items described in the instrument must reflect the most common signs encountered in the disease.
Reliability The degree to which scores are free from random (measurement) error.
Internal consistency
reliability
Extent to which items within each domain are interrelated.*
Test–retest reliability Stability of scores over time when no change is expected in the concept of interest.*
Concordance The degree of agreement among raters.
Construct validity It refers to whether an instrument measures intended theoretic constructs or traits and directly affects the appropriateness of the
measurement-based inferences.
Responsiveness to
change
The extent to which an instrument detects meaningful changes over time that have occurred after baseline.*
Convergent validity The degree to which the sign score correlates with other instruments measuring the same construct or with related clinical
indicators.†
Known-groups validity The extent to which the instrument can discriminate between groups that are known to differ on the variables being measured.*
Interpretability and
scoring
The degree to which the meaning of the scores can be easily understood.
Plan for scoring measure A description of how to score the measure should be provided (sum, algorithm).
Plan for missing data A prespecified plan for managing missing responses can mitigate the risk of bias resulting from the necessity to exclude cases with
missing data.
Scaling described The process of distributing the full range of respondents’ possible scores with respect to the measured attribute.
*Consistent: > 0.70 for group-level comparisons and 0.90–0.95 for individual comparisons.
†< 0.30 = low correlation; 0.30–0.60 = moderate correlation; > 0.60 = strong correlation (Pearson or Spearman analysis).
*Large change: > 0.80; moderate change: 0.50–0.79; small change: 0.2–0.49.
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TABLE II.
Characteristics of Included Publications
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
El-Serag,
2001 (17)
Monocentric Gr1: suspected LPR
(N = 10)
LPR symptoms and signs LE, EH, GG,
UC
Comp. Signs Score Gr1 = Gr2 12 w Gr1: Lansoprazole
(30 mg 2/d)
Placebo–RCT Gr2: suspected LPR
(N = 10)
Gr2: Placebo
Diet: −
Noordzij,
2001 (18)
Monocentric Gr1: LPR (N = 15) LPR symptoms VE, EH, GG,
LE,
Comp Signs Score 3 Gr1 = Gr2 8 w Gr1: Omeprazole
(40 mg, 2/d)
Placebo–RCT Gr2: LPR (N = 15) Dual-probe pH metry TM Gr2: Placebo (2/d)
Diet: −
Eherer,
2001 (18)
Monocentric Gr1: LPR (N = 7) Laryngeal symptoms GG, EH, PY,
VE,
Comp. Signs Score 7 Gr1 = Gr2 12 w Gr1: Pantoprazole
(40 mg, 2/d)
Placebo–RCT Gr2: LPR (N = 7) Dual-probe pH metry VR, PH, TM,
SE,
Gr2: Placebo
SP, SR, PP Diet: −
Steward,
2004 (20)
Monocentric Gr1: LPR (N = 21) LPR symptoms and signs EH, VE, LE,
PH,
Comp. Signs Score Gr1 = Gr2 8 w Gr1: Rabeprazole
(20 mg 2/d)
Placebo–RCT Gr2: LPR (N = 21) Dual-probe pH metry VR, GG, ND,
UC,
Gr1 and Gr2 t1 > t0 Gr2: Placebo
SE Diet: +
Vaezi,
2006 (21)
Multicentric Gr1: suspected LPR
(N = 95)
LPR symptoms EH, GG, LE,
PW
CPLI Gr1 = Gr2 16 w Gr1: Esomeprazole
(40 mg, 2/d)
Placebo–RCT Gr2: suspected LPR
(N = 50)
CPLI≥5 PH, VR, VE, Gr2: Placebo
Diet: −
Wo,
2006 (22)
Monocentric Gr1: LPR (N = 19) LPR symptoms (3/w) SE, VV, EH,
VE,
RFS Gr1 and 2: t1 > t0 12 w Gr1: Pantoprazole
(40 mg/d)
Placebo–RCT Gr2: LPR (N = 20) Triple-probe pH metry LE, PH, GG,
TM
Gr1 = Gr2 Gr2: Placebo
Diet: −
Reichel,
2008 (23)
Monocentric Gr1: suspected LPR
(N = 30)
RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS 6 w (Gr1 and 2) t1 > t0; t2 > t0 6, 12 w Gr1: Esomeprazole
(20 mg, 2/d)
Placebo–RCT Gr2: suspected LPR
(N = 28)
LE, PH, GG,
TM
Intergroup (6 w) Gr1 = Gr2 Gr 2: Placebo
RFS 12 w (Gr1 and 2) t1 > t0; t2 > t0 Diet: −
Intergroup (12 w) Gr1 > Gr2
Vashani,
2010 (24)
Monocentric Gr1: suspected LPR
(N = 16)
LPR symptoms and signs VE, LE, EH,
PW,
Vocal folds erythema and
edema
t1 > t0, Gr2 > Gr1 6 w Gr1: voice therapy
(2/w)+
Placebo–RCT Gr2: suspected LPR
(N = 16)
Hoarseness PO Pharyngeal erythema and
edema
t1 > t0, Gr2 > Gr1 Omeprazole (20 mg,
2/d)
Esophagitis Hypopharyngeal
erythema
t1 > t0, Gr2 > Gr1 Gr 2: Placebo (2/d)
Hypopharyngeal edema t1 > t0, Gr2 > Gr1 Diet: −
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TABLE II.
Continued
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
Vashani,
2010 (24)
Monocentric Gr1: suspected LPR
(N = 16)
LPR symptoms and signs VE, LE, EH,
PW,
Vocal folds erythema and
edema
t1 > t0, Gr2 > Gr1 6 w Gr1: voice therapy
(2/w)+
Placebo–RCT Gr2: suspected LPR
(N = 16)
Hoarseness PO Pharyngeal erythema and
edema
t1 > t0, Gr2 > Gr1 Omeprazole (20 mg,
2/d)
Esophagitis Hypopharyngeal
erythema
t1 > t0, Gr2 > Gr1 Gr 2: Placebo (2/d)
Hypopharyngeal edema t1 > t0, Gr2 > Gr1 Diet: −
McGlashan, 2009
(25)
Monocentric Gr1: suspected LPR
(N = 24)
RSI > 10 and RSF > 5 SE, VV, EH,
VE,
RFS (8 w) t1 > t0; Gr1 = Gr2 8, 24 w Gr1: Gaviscon (4/d)
Placebo–RCT Gr2: suspected LPR
(N = 25)
LE, PH, GG,
TM
RFS (24 w) t2 > t0; Gr1 = Gr2 Gr2: Placebo
Diet: +
Fass,
2010 (26)
Monocentric Gr1: suspected LPR
(N = 24)
LPR symptoms and signs SE, VV, EH,
VE,
RFS Gr1 = Gr2 12 w Gr1: Esomeprazole
(20 mg, 2/d)
Placebo–RCT Gr1: suspected LPR
(N = 17)
LE, PH, GG,
TM
Gr2: Placebo
Diet: +
Lam,
2010 (27)
Monocentric Gr1: suspected LPR
(N = 42)
LPR symptoms SE, VV, EH,
VE,
RFS (6, 12 and 18 w) Gr1 = Gr2 6, 12, Gr1: Rabeprazole
(20 mg, 2/d)
Placebo–RCT Gr2: suspected LPR
(N = 40)
RFS > 7 LE, PH, GG,
TM
18 w Gr2: Placebo
Diet: +
Ezzat,
2011 (28)
Monocentric Gr1: suspected LPR
(N = 42)
LPR symptoms and signs SE, VV, EH,
VE,
RFS Gr1 > Gr2 8 w Gr1: Pantoprazole
(40 mg/d) and
Placebo–RCT Gr2: suspected LPR
(N = 45)
LE, PH, GG,
TM
Itopride (50 mg, 3/d)
Gr2: Pantoprazole
(40 mg/d) and
Placebo
Diet: +
Tseng, Monocentric Gr1: LPR (N = 39) LPR symptoms and signs SE, VV, EH,
VE,
RFS t1 > t0; Gr1 = Gr2 8 w Gr1: Alginate
2018 (29) Placebo–RCT Gr2: LPR (N = 40) RSI > 10 and RFS > 5 LE, PH, GG,
TM
Gr2: Placebo
pH metry/impedance Diet: +
Siupsinkiene,
2003 (30)
MPC Gr1: suspected LPR
(N = 113)
LPR symptoms and signs LE, GG, PH Comp. Signs Score (2w) Gr1: S; Gr2 and 3:
NS
2 and 5 w Gr1: Omeprazole
(20 mg, 1–2/d)
Gr2: healthy (N = 113) Comp. Signs Score (5w) Gr1 and 3: S; Gr2:
NS
Gr2: Diet: +
Gr3: Nothing
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TABLE II.
Continued
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
Park,
2005 (31)
MPC Gr1: suspected LPR
(N = 30)
LPR symptoms and signs PW, PY, EH,
LE,
Comp. PL Score Prevalence of signs 16 w Gr1: Lansoprazole
(30 mg, 2/d)
Gr2: suspected (N = 30) PH, VR, VV,
VE,
No statistical evolu Gr2: Omeprazole
(20 mg, 2/d)+
Gr3: suspected (N = 25) SP, SR, GG tion provided Ranitidine (300 mg/d)
Gr3: Esomeprazole
(40 mg, 1/d)
Diet: +
Swoger,
2006 (32)
MPC Gr1: Uncured LPR
(N = 10)
LPR symptoms and signs PW, PY, EH,
LE,
Comp. PL Score Gr1 = Gr2 12, 52 w Gr1: Fundoplication
Gr2: Uncured LPR
(N = 15)
pH impedance/monitoring PH, VR, VV,
VE,
Gr2: Omeprazole
(80 mg/d)
Esophagoduodenoscopy SP, SR, GG or Lansoprazole
(120 mg/d)
Resistance to PPIs
treatment
Diet: +
Chung,
2012 (33)
MPC Gr1: suspected LPR
(N = 22)
RSI > 13 SE, VV, EH,
VE,
Gr1: RFS (4 w) t0 = t1, t1 > t0 4, 8 w Gr1: Lansoprazole
(30 mg 1/d)
Gr2: suspected LPR
(N = 20)
LE, PH, GG,
TM
Gr1: RFS (8 w) t1 > t0 Gr2: Lansoprazole +
SGB
Gr2: RFS (4 and 8 w) t1 > t0 Diet: NA
Gr Comparison Gr2 > Gr1 (4 and
8 w)
Oridate,
2012 (34)
MPC Gr1: suspected LPR
(N = 60)
LPR symptoms LE, PH, SE,
GG,
Modified RFS (t0, t1) Gr1 = Gr2 4 w Gr 1: Rabeprazole
(10 mg/d)
Gr2: suspected LPR
(N = 13)
Since at least 1 m TM, PI, EH Gr 2: No treatment
Diet. NA
Chun,
2013 (35)
MPC Gr1: suspected LPR
(N = 32)
RSI > 13 and RFS > 7 SE, VV, EH,
VE,
Gr1 and 2 (RFS) t1,2 > t0 6, 12 w Gr1: Lansoprazole
(30 mg/d)
Gr2: suspected LPR
(N = 29)
LE, PH, GG,
TM
Gr differences (6 and
8 w, RFS)
Gr1 = Gr2 Gr2: Lansoprazole
and
Itopride (50 mg, 3/d)
Diet: NA
Chappity,
2014 (36)
Monocentric Gr1: suspected LPR
(N = 117)
RSI > 13 DT, EH, LE,
NC,
Comp. Signs Score 8 Gr1 = Gr2 12 w Gr1: Omeprazole
(20 mg, 2/d)
RCT Gr2: suspected LPR
(N = 117)
PY, PW, VR,
PH
Gr2: diet
Diet: +
MPC Gr1: RSI > 13 and RFS > 7 RFS t1 > t0; Gr1 = Gr2 4 w
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Continued
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
Wan,
2014 (37)
Gr1: suspected LPR
(N = 35)
SE, VV, EH,
VE,
Esomeprazole (20 mg,
2/d)
Gr2: LPR (N = 23) Gr2: Dual-probe
pH/impedance
LE, PH, GG,
TM
Diet: +
Gr3: CT (N = 58) Metry
Ozturan,
2016 (38)
MPC Gr1: suspected LPR
(N = 65)
LPR symptoms SE, VV, EH,
VE,
RFS t1, t2 > t0 4, 8 w Esomeprazole (20 mg,
2/d)
Gr2: Control (N = 35) LE, PH, GG,
TM,
t2 Gr1 = Gr2 Diet: +
AN, UV, PO,
Hanson,
1995 (39)
MPUC Suspected LPR (N = 141) LPR symptoms and signs EH, LE, PH,
PW,
Hypopharyngeal and t1 > t0* 4 w Omeprazole (20 mg,
1/d)
GG, TM, KT Laryngeal signs Diet: +
Shaw,
1997 (40)
MPUC Suspected LPR (N = 96) LPR symptoms and signs EH, LE, UC,
GG
Comp. Signs Score 1 t1 > t0 12 w Omeprazole (20 mg/d)
Except granulation Diet: +
Habermann,
1999 (41)
MPUC Suspected LPR (N = 29) LPR symptoms and signs SP, SR, PH,
VR,
Comp. Signs Score 2 t1 > t0 6 w Pantoprazole (40 mg/
d)
Voice disorder VE, GG, PP,
UC,
Diet: −
LE, EH, LO, TI
Belfasky,
2001 (42)
MPUC LPR (N = 39) LPR symptoms and signs SE, VV, EH,
VE,
RFS t1, t2, t3 > t0 8, 16,
24 w
Omeprazole (20 mg,
2/d) or
Dual-probe pH metry LE, PH, GG,
TM
Rabeprazole (20 mg,
2/d) or
Lansoprazole (30 mg,
2/d)
Diet: +
Rodriguez,
2002 (43)
MPUC Suspected LPR (N = 21) LPR symptoms and signs TM, LH, EH,
UC,
Comp. Signs Score t1 > t0# 12 w Omeprazole (20 mg,
2/d)
GG #except granulation
score
Diet: −
Habermann,
2002 (44)
MPUC Suspected LPR (N = 24) LPR symptoms and signs VV, EH, VE,
LE,
Comp. Signs Score 4 t1 > t0 6 w Pantoprazole (40 mg/
d)
PH, GG, UC,
VR,
Diet: NA
SP, SR, PP
DelGaudio,
2003 (45)
MPUC Gr1: LPR responder
(N = 19)
LPR symptoms and signs VE, VR, LE,
GG,
Comp. Signs Score 5 4, 8 w Esomeprazole (40 mg
1/d)
Gr2: nonresponder
(N = 11)
Responder (8 w therapy) PH, TT, TM,
EH
Responder t1 > t0; t2 > t0 Diet: +
Nonresponder (pH metry+) Nonresponder t1 > t0; t2 > t0
(Continues)
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TABLE II.
Continued
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
Bilgen,
2003 (46)
MPUC Gr1: suspected LPR
(N = 36)
LPR symptoms and signs SE, VV, EH,
VE,
RFS t3 > t1 > t0 12, 16,
24 w
Lansoprazole (30 mg,
2/d)
Gr2: CT (N = 23) LE, PH, GG,
TM
Diet: +
Garrigues,
2003 (47)
MPUC Suspected LPR (N = 91) LPR symptoms and signs GG, UC, LO,
TM,
Comp. Signs Score 6 t2 > t1 > t0* 12 and
24 w
Omeprazole (20 mg,
2/d)
EH, VR, SR Diet: NA
Beaver,
2003 (9)
MPUC Suspected LPR (N = 49) LPR symptoms and signs PH, SP, SE,
VR,
LPR disease index
(photos)
t1 > t0 6 w Lansoprazole (30 mg,
2/d)
SR, SU, ND,
PP,
Omeprazole (20 mg,
2/d)
LL, GG, WW Pantoprazole (40 mg,
2/d)
Rabeprazole (20 mg,
2/d)
Diet: NA
Williams,
2004 (48)
MPUC Suspected LPR (N = 20) LPR symptoms and signs LE, EH, VE, VR Laryngoscopic Grading
Score
t1 > t0 12 w Omeprazole (20 mg,
3/d)
Since at least 3 m SE, SU, UC Diet: +
Sereg-Bahar,
2005 (49)
MPUC Suspected LPR (N = 43) LPR symptoms and signs SE, VV, EH,
VE,
RFS t1 > t0 8 w Esomeprazole
(40 mg/d)
LE, PH, GG,
TM
Diet: +
Qaader,
2005 (10)
MPUC Gr1: LPR (N = 72) LPR symptoms and signs PY, PW, GG,
EH,
Comp. Signs Score v1 t1 > t0; t2 > t1 16 w, 54 w Gr1: Omeprazole
(40 mg, 2/d)
Gr2: LPR (N = 10) pH metry PH, KT, LE,
VE,
or Lansoprazole
(60 mg, 2/d)
GERD VR, PP, SP,
SR
Gr2: Fundoplication
Resistance to PPIs
treatment
Diet: NA
Qua,
2007 (50)
MPUC Suspected LPR (N = 32) LPR symptoms and signs LE, EH, VE, VR Laryngoscopic Grading
Score
Gr1 > Gr2 8 w Lansoprazole (30 mg,
2/d)
Gr1: GERD (N = 21) SE, SU, UC Gr1–Gr2 t1 > t0; t1 = t0 Diet: −
Gr2: non-GERD (N = 11)
Jin,
2008 (51)
MuPUC LPR (N = 40) LPR symptoms and signs SE, VV, EH,
VE,
RFS t2,3,4,5 > t0 2, 4, 8, 12, Lansoprazole (30 mg/
d)+
Dual-probe pH metry LE, PH, GG,
TM
16, 20 w Levosulpiride (25 mg,
3/d) or
Mosapride (5 mg, 3/d)
Diet: NA
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TABLE II.
Continued
References Design Characteristics Inclusion Criteria Signs Sign Outcomes Results ET Treatment
Koufman, MPUC Resistant LPR (N = 20) Resistance to PPI+Anti-H2 SE, VV, EH,
VE,
RFS t1 > t0 2 w 1. Strict diet
2011 (52) Dual-probe pH metry LE, PH, GG,
TM
Lee,
2011 (4)
MuPUC Suspected LPR (N = 455) LPR symptoms and signs SE, VV, EH,
VE,
RFS t1 > t0 12 w Rabeprazole
(10/20 mg/d)
LE, PH, GG,
TM
Diet: +
Masaany,
2011 (53)
MPUC Suspected LPR (N = 47) RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS t3 > t0; t2 > t0;
t1 > t0
8, 12,
16 w
Pantoprazole (40 mg,
2/d)
LE, PH, GG,
TM
Diet: NA
Naiboglu,
2011 (54)
MPUC Suspected LPR (N = 50) Esophagitis SE, VV, EH,
VE,
RFS t1 > t0 12 w Lansoprazole (30 mg/
d)
RS1 > 13 and RFS > 7 LE, PH, GG,
TM
Diet: +
Patigaroo,
2011 (55)
MPUC Suspected LPR (N = 50) RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS (8, 16 w) t1 = t0, t2 > t1 8, 16 w (Es)/omeprazole
(20 mg, 2/d)
LE, PH, GG,
TM
Lansoprazole (30 mg,
2/d)
Pantoprazole (40 mg,
2/d)
Diet: NA
Habermann,
2012 (56)
MuPUC Suspected LPR (N = 1044) RSI > 9 and RFS > 7 SE, VV, EH,
VE,
RFS t1 > t0 8–12 w Pantoprazole (20 or
40 mg, 2/d)
LE, PH, GG,
TM
Diet: NA
Park,
2012 (57)
MPUC Gr1: suspected LPR
(N = 50)
RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS (4 and 8 w) Gr2 = Gr1 4, 8, 12 w Gr1: Omeprazole
(20 mg, 2/d)
Gr2: suspected LPR
(N = 50)
LE, PH, GG,
TM
RFS (4, 8, 12 w) Gr2 > Gr1 Gr2: Omeprazole +
Voice therapy
Diet: −
Vailati,
2013 (74)
MPUC Suspected LPR (N = 22) RSI > 13 SE, VV, EH,
VE,
RFS t1 > t0 12 w Pantoprazole (40 mg,
2/d)
LE, PH, GG,
TM
Diet: NA
Lee,
2014 (58)
MuPUC Suspected LPR (N = 180) LPR symptoms and signs SE, VV, EH,
VE,
RFS t1 > t0 12 w Lansoprazole (15 mg,
2/d)
LE, PH, GG,
TM
Diet: +
(Continues)
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Semmanaselvan,
2015 (59)
MPUC Suspected LPR (N = 50) RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS t1 > t0 12 w 1. Rabeprazole
(20 mg/d)
LE, PH, GG,
TM
2. Domperidone
(30 mg/d)
Diet: NA
Batioglu,
2016 (60)
MPUC Suspected LPR (N = 84) RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS t1 > t0 12 w Lansoprazole (30 mg,
2/d)
LE, PH, GG,
TM
Diet: NA
Dulery,
2016 (61)
MPUC Suspected LPR (N = 24) LPR symptoms SE, VV, EH,
VE,
RFS t0 = t1 8 w Esomeprazole (40 mg,
2/d)
LE, PH, GG,
TM
Diet: NA
Joshi,
2017 (62)
MPUC Suspected LPR (N = 100) LPR symptoms SE, VV, EH,
VE,
RFS t3 > t2 > t0 4, 8, 24 w Omeprazole (20 mg,
2/d)
LPR signs: RFS > 7 LE, PH, GG,
TM
Diet: +
TT
Pullarat,
2017 (63)
MPUC Suspected LPR (N = 30) LPR symptoms SE, VV, EH,
VE,
RFS t1 > t0 8 w Pantoprazole (40 mg/
d)
Hoarseness since > 3 w LE, PH, GG,
TM
Diet: NA
TT
Lechien,
2018 (5)
MuPUC LPR (N = 80) RSI > 13 and RFS > 7 SE, VV, EH,
VE,
RFS t1 > t0 12 w Pantoprazole (20 mg,
2/d)
pH metry (resistant
patients)
LE, PH, GG,
TM
Diet: +
TT
Gupta,
2016 (11)
Monocentric Suspected LPR (N = 188) LPR symptoms SE, VV, EH,
VE,
RFS t1 > t0 10 w PPIs (2/d)
Retrospective LPR signs LE, PH, GG,
TM
Diet: NA
TT
AN = anterior pillars erythema/edema; CPLI = chronic posterior laryngitis index; d = day; ET = evaluation time; EH = laryngeal/arytenoids erythema; GG = interarytenoid granulation and/or granuloma; Gr =
group; KT = laryngeal keratosis; LE = laryngeal edema; LGS = laryngoscopic grading scale; LL = leukoplakia; LO = loss light reflect; LPR = laryngopharyngeal reflux; LRDI = laryngopharyngeal reflux disease index;
LRG = laryngeal reflux grade; MPC = monocentric prospective controlled study; M(Mu)PUC = monocentric (multicentric) prospective uncontrolled study; NC = nasal congestion; ND = nodules; PH = posterior com-
missure hypertrophy; PI = mucous pooling in the pyriform sinus; PO = posterior oropharyngeal wall erythema; PP = polyp/Reinke edema; PW = posterior pharyngeal wall erythema; PY = postpharyngeal cobbleston-
ing; RCT = randomized controlled trial; RFS = reflux finding score; RSI = reflux symptom index; SE = subglottic edema/pseudosulcus/stenosis; SP = supraglottis edema; SR = supraglottis erythema;
SU = subglottic erythema; TM = thick endolaryngeal mucus; t = time; TT = tongue tonsil hypertrophy; UC = laryngeal ulcerations; UV = uvula erythema/edema; VE = vocal fold edema; VR = vocal fold erythema;
VV = ventricular obliteration; w = week; WW = vocal web.
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TABLE III.
Objectives, Targeted Population, Population Characteristics, Setting, and Instrument Characteristics for LPRD Sign Validated Instruments
Instrument Year
Language/
Country
Validation/
Standard Objective
Target and Patient
Characteristics Setting
Scale Characteristics
Signs Type Item (N) Item Response Calculation Subscales
RFS (42) 2001 U.S. + Diagnosis Suspected LPR Monocenter SE, VV, EH,
VE,
PRI 8 Severity: 0–4 Sum of items 0
Therapeutic LPR Tertiary
center
LE, PH, GR,
TM
or 0–2 Total score:
26
outcome Age: 52 y Controlled
Gender: 29 F/11 M Prospective
Vaezi 2002 U.S. + Diagnosis Uncured LPR Monocenter PY, PW, GG,
EH,
Yes/
No
12 Presence: yes/no Sign
prevalence
0
Instrument
(64)
Therapeutic Gender: 18 F, 7 M Sec/ter
center
PH, KT, LE,
VE,
Total score:
NA
outcome Age: 39.9 y VR, PP, SP,
SR
LRDI (9) 2003 U.S. + Therapeutic Suspected LPR Monocenter PH, SP, SE,
VR,
VAS 12 Severity: 0–3 Sum of items 0
outcome Gender: NA Tertiary
center
SR, SU, ND,
PP,
Total score:
36
Age: NA LL, GG, WW
LGS (48) 2004 Australia + Therapeutic Suspected LPR Monocenter LE, EH, VE,
VR
PRI 4 Laryngitis grade:
0–4
– 0
outcome Gender: 11 F, 9 M Sec/ter
center
SE, SU, UC Each grade is
defined
Age: 55 y
LRG (20) 2004 U.S. + Therapeutic LPR Monocenter EH, VE, LE,
PH,
Likert Signs: 6 Severity: 0–4 Sum of items Sign scale
outcome Gender: 30 F, 12 M Sec/ter
center
VR, GG, ND,
UC,
Scale VC
wave:
Total score:
24 + 16
VC wave
Age: 49.3 y Placebo–
RCT
SE 4
CPLI (21) 2006 U.S. + Therapeutic Suspected LPR Monocenter EH, GG, LE,
PW
VAS 10 Severity: 0–3 Sum of items 0
outcome Gender: 74 F, 71 M Sec/ter
center
PH, VR, VE Total score:
30
Age: 51 y Placebo–
RCT
+ = criterion met; AN = anterior pillars erythema/edema; CPLI = chronic posterior laryngitis index; EH = Laryngeal/arytenoids erythema; F = female; GG = interarytenoid granulation and/or granuloma; KT =
laryngeal keratosis; LE = laryngeal edema; LGS = laryngoscopic grading scale; LL = leukoplakia; LO = loss light reflect; LPR = laryngopharyngeal reflux; LRDI = laryngopharyngeal reflux disease index; LRG = laryn-
geal reflux grade; M = male; NA = not available; NC = nasal congestion; ND = nodules; N.E. = not evaluable; PH = posterior commissure hypertrophy; PI = mucous pooling in the pyriform sinus; PO = posterior oro-
pharyngeal wall erythema; PP = polyp/Reinke edema; PRI = predefined item; PW = posterior pharyngeal wall erythema; PY = postpharyngeal cobblestoning; RCT = randomized controlled trial; RFS = reflux finding
score; sec = secondary; SE = subglottic edema/pseudosulcus/stenosis; SP = supraglottis edema; SR = supraglottis erythema; SU = subglottic erythema; TM = thick endolaryngeal mucus; TT = tongue tonsil hyper-
trophy; UC = laryngeal ulcerations; UV = uvula erythema/edema; VAS = visual analog scale; VC = vocal cords; VE = vocal fold edema; VR = vocal fold erythema; VV = ventricular obliteration; WW = vocal web;
y = year.
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Analysis of Validated ICFs
RFS42 is the most common validated ICF in the liter-
ature (N = 31 of 53), followed by the composite score
developed by the group of Vaezi (N = 3 of 53), which we
refer to as the Vaezi instrument. Notably, this instrument
was validated over four studies.10,31,32,64 The remaining
validated ICFs were used only in their validation study.
We did not identify other authors who used these ICFs in
their studies. Thus, these ICFs are limited in scope. The
measurement properties of the six validated ICFs are
described in Table V. Overall, no ICF met all the vali-
dated criteria described in Table I.
CONCEPTUAL MODEL AND CONTENT
VALIDITY. The conceptual model was adequately
described in all references describing ICF validation.
Descriptions of the item development and the appropria-
tion of all the LPRD instruments were provided in all the
publications. Concerning instrument development, no
instrument was based on a clinical study that assessed
the prior prevalence of all ENT findings among patients
with LPRD. The content of all ICFs was based on the
opinions of experts (i.e., otolaryngologists, gastroenterolo-
gists, and/or speech therapists). However, some laryngeal
and many extralaryngeal signs were not considered in
the elaboration of all ICFs, particularly the LGS, CPLI,
and RFS.
RELIABILITY. The reliabilities of four instruments
were assessed via test–retest reliability. Of these instru-
ments, the RFS and LRG exhibited consistent overall
test–retest reliability. Concerning individual items, RFS
showed initially consistent reliability and LRG had
moderate-to-high reliability. However, additional studies
did not confirm the high reliability of the RFS.71 The reli-
abilities of the LRDI and Vaezi instruments were lower.
Test–retest reliability analyses were not reported for
either LGS or CPLI. Based on interrater reliability
(i.e., concordance), the RFS and LGS exhibited higher
concordance than did the LRDI and Vaezi instrument. No
instrument was tested for internal consistency.
CONSTRUCT VALIDITY. Known-groups validity
was statistically demonstrated with regard to the RFS,
Fig. 1. Flow chart shows the process of article selection for this study.
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LRDI, and Vaezi instruments. Other instruments did not
provide comparisons between LPR patients and controls.
Responsiveness to change, especially as assessed throughout
the therapeutic course, was satisfactory with regard to all
ICFs. In the current literature, the RFS significantly
improved over treatment according to 25 studies (Table II).
Concerning the Vaezi instrument, only Qaader et al.10 found
substantial improvement of the score throughout treatment.
No instrument was tested for convergent validity.
INTERPRETABILITY AND SCORING. All the
publications provided scoring (i.e., calculation) details.
The scoring system substantially varied across instru-
ments. The majority of the instruments had a total score
that corresponded to the sum of the item scores where
higher total scores indicated more severe LPRD signs.
Thus, the addition of each item score from the RFS,
LRDI, CPLI, and LRG led to a total score ranging from
a minimum of 0 to a maximum of 4 to 40 depending on
the instrument. The Vaezi instrument does not have a
total score because it is based on the presence or absence
of signs. In addition, the Vaezi instrument was not con-
structed to sum all item scores. Regarding interpretabil-
ity, only the RFS determined a diagnosis cutoff
(RFS = 7) for an abnormal score that could be combined
with a reflux symptom index > 13 to represent a high
probability of LPRD. With regard to the other ICFs, we
did not find cutoff or severity thresholds with clinical
significance.
Bias Analysis
Many studies included patients suspected as having
LPR without a formal diagnosis. The heterogeneity of the
TABLE IV.
Assessed Signs in Validated, Unvalidated Instruments, and in the Literature
Signs in Instruments (N = 16) N Signs in Number of Studies: N = 53
Laryngopharyngeal Laryngopharyngeal
Laryngeal/arytenoids erythema EH 15 Laryngeal/arytenoids erythema EH 51
Laryngeal edema LE 14 Granuloma/granulation (interarytenoid nodularity) GG 49
Posterior commissure hypertrophy PH 11 Laryngeal edema LE 45
Vocal fold edema VE 10 Posterior commissure hypertrophy PH 44
Thick endolaryngeal mucous TM 7 Vocal fold edema VE 38
Subglottic edema/pseudosulcus/stenosis SE 6 Thick endolaryngeal mucous TM 37
Granuloma/granulation (interarytenoid nodularity) GG 12 Subglottic edema/pseudosulcus/stenosis SE 49
Ventricular obliteration VV 2 Ventricular obliteration VV 34
Vocal fold erythema VR 11 Vocal fold erythema VR 14
Vocal cord epithelium thickening TI 2 Laryngeal ulcerations UC 1
Laryngeal ulcerations UC 5 Supraglottis erythema SR 9
Posterior pharyngeal wall erythema PW 3 Posterior pharyngeal wall erythema PW 7
Supraglottis edema SP 4 Supraglottis edema SP 7
Supraglottis erythema SR 6 Polyp/Reinke edema PP 8
Leukoplakia LL 1 Postpharyngeal cobblestoning PY 1
Polyp/reinke edema PP 4 Subglottic erythema SU 5
Postpharyngeal cobblestoning PY 3 Loss light reflect LO 5
Loss light reflect LO 2 Nodules ND 2
Nodules ND 2 Leukoplakia LL 2
Vocal web WW 1 Vocal cord epithelium thickening TI 1
Laryngeal keratosis KT 1 Vocal web WW 2
Mucous pooling in the pyriform sinus PI 1 Laryngeal keratosis KT 1
Subglottic erythema SU 2 Mucous pooling in the pyriform sinus PI 3
Extralaryngopharyngeal Extralaryngopharyngeal
Tongue tonsil hypertrophy TT 1 Tongue tonsil hypertrophy TT 5
Nasal congestion NC 1 Posterior oropharyngeal wall erythema PO 1
Uvula erythema/edema UV 0 Nasal congestion NC 1
Anterior pillars erythema/edema AN 0 Uvula erythema/edema UV 1
Posterior oropharyngeal wall erythema PO 0 Anterior pillars erythema/edema AN 2
Dull tympanic membrane DT 1 Dull tympanic membrane DT 1
AN = anterior pillars erythema/edema; EH = laryngeal/arytenoids erythema; GG = interarytenoid granulation and/or granuloma; KT = laryngeal keratosis;
LE = laryngeal edema; LL = leukoplakia; LO = loss light reflect; NC = nasal congestion; ND = nodules; PH = posterior commissure hypertrophy; PI = mucous
pooling in the pyriform sinus; PO = posterior oropharyngeal wall erythema; PP = polyp/Reinke edema; PW = posterior pharyngeal wall erythema; PY = postphar-
yngeal cobblestoning; SE = subglottic edema/pseudosulcus/stenosis; SP = supraglottis edema; SR = supraglottis erythema; SU = subglottic erythema; TM =
thick endolaryngeal mucus; TT = tongue tonsil hypertrophy; UC = laryngeal ulcerations; UV = uvula erythema/edema; VE = vocal fold edema; VR = vocal fold
erythema; VV = ventricular obliteration; WW = vocal web.
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inclusion criteria across studies can lead to differences in
the profiles of the patients with LPR who comprised the
validation studies. This point is consistent with a
selection bias.
In a large majority of the studies, physicians were
not blinded to the description of LPRD signs based on
symptoms. Moreover, one study21 proposed specialized
training to improve/standardize the evaluation of signs
among physicians before they could be assessed with an
ICF. The training of judges can bias certain measurement
properties such as concordance (i.e., interrater reliability).
These two points represent the possibility of an evalua-
tion/detection bias.
In addition, we identified various therapeutic regi-
mens including the use of PPIs in association with other
drugs (i.e., alginate, antihistamine, or gastroprokinetic)
or diet. Because the changes in signs over treatment
depend on the therapy, the therapeutic variability and
the lack of a treatment demonstrated as superior to pla-
cebo might bias the assessment of responsiveness to
change. The lack of inclusion of many signs related to
LPRD in ICFs might also bias an overall patient response
to treatment that is consistent with an evaluation bias.
Supporting Table SII). provides risk of bias assessment
according to studies.
DISCUSSION
The use of patient-reported outcome measures, ICFs,
or both has become standard in studies assessing the effi-
ciency of a treatment.65 Measurement instruments are
useful for collecting precise data for the initial evaluation
of patient symptoms and signs and the assessment of
treatment effectiveness. This point is particularly rele-
vant with regard to LPRD and the low specificity of its
signs and symptoms given the existing controversies
regarding the superiority of PPIs over placebo.66
In this systematic review, we identified 16 ICFs,
which included 10 unvalidated tools and six instruments
that met at least one developmental measurement prop-
erty criterion. The usefulness of an outcome measure-
ment instrument is related to its intent and the quality of
its development. Of the 6 ICFs that underwent psycho-
metric evaluation, only RFS met the following validation
criteria: construct definition, content validity, reliability,
concordance, known-group validity, responsiveness to
change, and interpretability and scoring.42 However, the
initial version of the RFS was not evaluated for internal
consistency or convergent validity. Four other instru-
ments (i.e., the LRG, LRDI, LGS, and Vaezi instrument)
provided partial validation of two to six validated concep-
tual properties. The CPLI does not have documented reli-
ability or construct validity. Of these six ICFs, only RFS
and the Vaezi instrument were conceived for both diagno-
sis and therapeutic outcomes.42,64
Input from the targeted subject population is crucial
establish an instrument’s content validity because it
ensures that all relevant signs are included and that the
instrument accurately assesses the concepts of interest
for physicians. The target population of the included stud-
ies consisted of patients suspected9,48 or confirmed as
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having LPR.20,21,42,64 Our review showed that the diagno-
sis criteria substantially varied across studies regarding
symptoms, signs considered for a LPRD diagnosis, or the
diagnostic thresholds used for pH impedance monitoring.
Of the studies that applied a clinical diagnosis, the major-
ity did not provide information about the exclusion cri-
teria or did not exclude major cofounding factors such as
smoking or alcoholism,64 infections within the last month,
or active allergies,9,42 which all represent a selection bias.
In fact, the inclusion or exclusion criteria of a specific
study population can have a dramatic effect on the con-
clusions regarding the effectiveness of a treatment.67
Thus, the lack of sensitivity of pH metry/impedance, the
inclusion of certain confounds, and the disparity in the
LPRD diagnosis methods undeniably affect how current
measures define their targeted populations. In addition,
the number of patients included in validation studies was
low ( < 100), although it is recommended to have at least
100 participants to optimize component/factor-analysis–
based methods.68
Experienced otolaryngologists have examined the
content of all validated ICFs with regard to the specific
signs that are usually treated in their practice. No study
based the content elaboration on the prevalence of LPR
signs. Because of the definition of the target population,
the content of an ICF is important for its psychometric
validation. Our analysis of the signs available in the vali-
dated tools reported an important level of heterogeneity
among the signs assessed for LPR diagnosis or as a thera-
peutic outcome. We also observed an overreliance on the
same laryngeal signs, especially those described in RFS,
and a lack of consideration of other laryngeal (i.e., vocal
fold erythema, leukoplakia, and keratosis) and extralar-
yngeal signs (i.e., tongue tonsil hypertrophy, posterior
pharyngeal wall and anterior pillars erythema, edema,
coated tongue), although they seemed to concern a consid-
erable number of patients according to previous clinical
reports.7,8,39,45,69 The lack of consideration of these signs
might significantly affect the development of an instru-
ment and its usefulness as a diagnostic tool (i.e., patient
inclusion) or therapeutic outcome.
Reliability reflects an instrument’s stability over
time and between different investigators. Our analysis
identified high test–retest reliabilities for the RFS42 and
LRG,20 as well as moderate-to-high reliability for the
LRDI9 and Vaezi instrument.64 In all studies, the test–
retest procedures were consistent with the recommenda-
tions of the current literature.70 The reliability of an
instrument also involves a high degree of rater agree-
ment. The initial publications describing the RFS and
LGS reported higher interrater agreements, ranging from
0.75 to 0.93.42,48 However, Chang et al. independently
assessed the reliability of RFS among general otolaryn-
gologists and found only a fair level of concordance (corre-
lation coefficient = 0.586) among raters.71 Belafsky
et al. studied two physicians who provided the analysis,
came from the same center, and benefited from the same
training, explaining the high concordance values com-
pared with other studies.42 Moreover, a key point that
might explain the better concordance for LGS concerns
the rating system of their items because it corresponded
to a clear definition of an identified sign. In other words,
the assessment of the severity of a sign using a VAS is
more subject to interrater differences because it is more
subjective and related to the knowledge and experience of
the physician71 than an instrument in which each rating
is well-defined. However, the concordances of the LRDI9
and Vaezi instrument64 based on their sign evaluation on
a VAS were lower than those of the RFS42 and LGS,48
even though the authors of these two studies followed the
usual recommended procedures. In addition, concordance
seems to depend on the signs evaluated. As such, Beaver
et al. showed that certain signs, especially leukoplakia,
nodules or prenodules, and contact granulomas, had the
highest levels of agreement compared with edema and
erythema of laryngeal spaces.9 Thus, evaluating the
interrater reliability is important for the total score and
each item.
The validity of an instrument depends on its ability
to detect differences between independent groups using
between-participant statistics, which corresponds to
known-groups validity. The LRDI, RFS and Vaezi instru-
ment provided consistent results in their respective case-
control studies comparing healthy participants and
patients.21,42,64 Nevertheless, the numbers of healthy par-
ticipants included in these case-control studies were low,
and the selection criteria for these participants were
rarely described. Concerning the interpretability of a
score, we found critical thresholds for RFS only because
Belafsky et al. determined that a combination of RFS > 7
and RFS > 13 is highly correlated with an LPRD
diagnosis.42,72
Finally, the construct validity of an instrument
involves its ability to measure responsiveness to change
that strongly depends on the content, reliability, and
validity of the outcome measurement instrument. Hence,
the lack of consideration of certain typical findings
related to LPRD might negatively affect responsiveness
to change. In fact, we and other authors66 suspect that
the controversial results of placebo-randomized controlled
trials are partially due to the lack of complete, reliable
tools evaluating both the signs and symptoms of LPRD.
This point concerns all the ICFs described in the present
review, including RFS. Thus, RFS does not include extra-
laryngeal signs or laryngeal signs (i.e., leukoplakia, vocal
fold erythema, subglottic erythema, and thickening of the
vocal fold epithelium). However, as the first and most
well-known clinical instrument regarding LPRD, RFS
remains commonly used around the world. Moreover,
patients with leukoplakia and granuloma were excluded
during the development of RFS,42 although they might be
related to LPR.8 Responsiveness to change is based on a
physician’s perception of signs, which involves an unbi-
ased evaluation of clinical findings. Our analysis revealed
that many physicians assessed laryngoscopic signs with
knowledge of the patient’s symptoms.20,21,42,64 Only Bea-
ver et al. performed blinded evaluations via clinical trials
involving a laryngoscopic examination.9 The unblinded
assessment of laryngoscopic signs increases the risk of
misjudging the sign score because LPR studies have dem-
onstrated that the perception of a sign can be influenced
by the physician’s personal knowledge, its understanding
Laryngoscope 00: Month 2018 Lechien et al.: Laryngopharyngeal Reflux Findings
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within the clinical area, and knowledge of the patient’s
complaints.71,73 For these reasons, the assessment of
signs must be blinded according to both the patient’s
state (LPR vs. healthy) and their complaints to provide
reliable instrument development. In clinical practice,
with regard to the subjectivity in the assessment of signs,
the poor specificity of signs, and low interjudge reliability,
future ICFs could comprise scores with precise descrip-
tions of the item grade of each sign. In other words,
future ICFs could avoid the grading of signs with a VAS
that remains objective and related to physician abilities.
The development of software that can objectify the degree
of inflammation of the mucosa on the basis of redness
intensity could also aid physicians in the clinical
evaluation.
Finally, no ICFs provided internal consistency or
convergent analyses. Regarding the limitations of this
review, first, we limited our research to publications in
the English and French languages and excluded unpub-
lished ICFs. Second, judgments of instrument character-
istics were based on the analysis of three independent
physicians. Even if this procedure minimizes the risk of
the biases related to the subjectivity of the task, these
biases remain possible. Third, the low number of patients
in all included studies and their methodological biases
might have affected our psychometric analysis. Four,
many authors selected their LPR patients on the basis of
symptoms and signs without additional examination.
Potentially, these cohorts of suspected LPR patients
included subjects without LPRD, which can also nega-
tively impact the treatment efficiency and related respon-
siveness to change.
CONCLUSION
With patient-reported questionnaires, ICFs have an
important place in LPRD diagnosis and evaluation of
treatment effectiveness. To date, only a few ICFs have
been developed, and none currently meet all clinical and
regulatory requirements. The main impairments related
to their psychometric validation include variable con-
struct validity, disparate and uncertain reliabilities, and
lack of interpretability. Moreover, no current instrument
takes into account a full assessment of laryngeal and
extralaryngeal signs related to LPRD, hindering content
and construct validities. The development of further com-
plete, reliable ICFs is particularly important with regard
to the low specificity of both signs and symptoms related
to LPRD and the lack of a gold standard for the
diagnosis.
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